Ruxolitinib Appears Effective as Treatment of Steroid-Refractory GVHD
Uday R. Popat, MD, discusses the role of ruxolitinib as treatment of patients with graft-versus-host-disease.
Uday R. Popat, MD, professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of ruxolitinib (Jakafi) as treatment of patients with graft-versus-host-disease (GVHD).
In the first-line setting, treatment of GVHD is typically steroids. However, patients who end up failing treatment with steroids tend to have dismal outcomes. Over the years, Popat says multiple regimens have been evaluated as a potential new treatment for patients with GVHD, particularly those who become steroid-refractory.
The first treatment to show benefit was ruxolitinib, the JAK inhibitor. The objective response rate falls north of 50%, Popat says, which is impressive in this steroid-refractory population. For any patient who fails steroids, ruxolitinib is a good agent to use in the second-line setting.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More
